The results showed that SKBR3 (as HER2-positive cells) exhibits much stronger SERS signals than MCF7 (as HER2 negative cells), indicating that the SERS probe potentially can distinguish the HER2 status of different kinds of breast cancer cells [69,71]. This evidence concerns the gene ERBB2 and breast carcinoma.